{"id":"ibrutinib-oral-capsule","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Bruising/bleeding"},{"rate":"20-30","effect":"Infection"},{"rate":"15-25","effect":"Rash"},{"rate":"5-10","effect":"Atrial fibrillation"},{"rate":"5-10","effect":"Pneumonia"}]},"_chembl":{"chemblId":"CHEMBL1873475","moleculeType":"Small molecule","molecularWeight":"440.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibrutinib irreversibly binds to and inhibits Bruton's tyrosine kinase, a key enzyme in B-cell receptor signaling. By blocking BTK, the drug prevents activation and proliferation of B-cell malignancies while also modulating the tumor microenvironment. This mechanism is particularly effective in B-cell lymphomas and leukemias that depend on BCR signaling for survival.","oneSentence":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:20.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Mantle cell lymphoma (MCL)"},{"name":"Marginal zone lymphoma (MZL)"},{"name":"Waldenström macroglobulinemia (WM)"}]},"trialDetails":[{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT05963074","phase":"PHASE2","title":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-05-30","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma","enrollment":320},{"nctId":"NCT01804686","phase":"PHASE3","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma","enrollment":700},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT03514017","phase":"PHASE2","title":"Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-05-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT04421560","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT03697512","phase":"PHASE2","title":"MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2019-09-27","conditions":"Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma","enrollment":175},{"nctId":"NCT03960840","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-26","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":217},{"nctId":"NCT04008706","phase":"PHASE3","title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":552},{"nctId":"NCT03790332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2018-11-19","conditions":"Chronic Graft Versus Host Disease","enrollment":59},{"nctId":"NCT05105841","phase":"PHASE2","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-11-08","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":20},{"nctId":"NCT05564052","phase":"PHASE2","title":"A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Lymphoma, Mantle-Cell","enrollment":36},{"nctId":"NCT02315768","phase":"PHASE1, PHASE2","title":"Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-08-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":32},{"nctId":"NCT07169565","phase":"PHASE1","title":"Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-01","conditions":"Waldenström Macroglobulinemia (WM)","enrollment":21},{"nctId":"NCT01589302","phase":"PHASE2","title":"PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2012-05-21","conditions":"Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia","enrollment":154},{"nctId":"NCT04212013","phase":"PHASE3","title":"A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-23","conditions":"Marginal Zone Lymphoma","enrollment":23},{"nctId":"NCT04477486","phase":"PHASE2","title":"Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-09-23","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":13},{"nctId":"NCT01776840","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-16","conditions":"Mantle Cell Lymphoma","enrollment":523},{"nctId":"NCT03328078","phase":"PHASE1, PHASE2","title":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","status":"RECRUITING","sponsor":"Curis, Inc.","startDate":"2017-12-28","conditions":"Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma","enrollment":152},{"nctId":"NCT04042376","phase":"PHASE4","title":"A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Waldenstrom Macroglobulinemia","enrollment":17},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT03190330","phase":"PHASE4","title":"A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2019-06-26","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell","enrollment":75},{"nctId":"NCT02329847","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-03-11","conditions":"Hematologic Neoplasms","enrollment":144},{"nctId":"NCT04685915","phase":"PHASE2","title":"Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL","status":"WITHDRAWN","sponsor":"Inhye Ahn","startDate":"2021-02-18","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":""},{"nctId":"NCT02966730","phase":"EARLY_PHASE1","title":"Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-11","conditions":"Follicular Lymphoma, Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2","enrollment":2},{"nctId":"NCT03295240","phase":"EARLY_PHASE1","title":"The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-20","conditions":"Mantle Cell Lymphoma, Lymphoma","enrollment":10},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT03474679","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2018-05-01","conditions":"Graft vs Host Disease","enrollment":19},{"nctId":"NCT02638116","phase":"PHASE1","title":"A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT02232386","phase":"PHASE2","title":"Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2015-03-02","conditions":"Chronic Lymphocyte Leukemia, Adult Patients","enrollment":156},{"nctId":"NCT02910583","phase":"PHASE2","title":"Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2016-09-28","conditions":"Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":323},{"nctId":"NCT02268851","phase":"PHASE1","title":"A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT01724346","phase":"PHASE3","title":"Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-12-03","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":269},{"nctId":"NCT04274738","phase":"PHASE1","title":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","status":"COMPLETED","sponsor":"X4 Pharmaceuticals","startDate":"2020-04-30","conditions":"Waldenstrom's Macroglobulinemia","enrollment":16},{"nctId":"NCT02451111","phase":"PHASE2","title":"Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2015-11-06","conditions":"Follicular Lymphoma","enrollment":190},{"nctId":"NCT03684694","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"ADC Therapeutics S.A.","startDate":"2018-12-01","conditions":"Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":136},{"nctId":"NCT03399513","phase":"PHASE2","title":"Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2018-05-03","conditions":"Diffuse Large B Cell Lymphoma","enrollment":40},{"nctId":"NCT03689894","phase":"PHASE1, PHASE2","title":"Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2019-04-11","conditions":"Chronic Graft-versus-host-disease","enrollment":2},{"nctId":"NCT02352558","phase":"PHASE1","title":"A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-05","conditions":"Hematologic Malignancy","enrollment":15},{"nctId":"NCT04016805","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2019-08-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":41},{"nctId":"NCT02959944","phase":"PHASE3","title":"Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-05-11","conditions":"Chronic Graft Versus Host Disease","enrollment":193},{"nctId":"NCT03876028","phase":"PHASE1","title":"Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT03873493","phase":"PHASE2","title":"A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-01-14","conditions":"Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer","enrollment":14},{"nctId":"NCT03280160","phase":"PHASE2","title":"Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2017-09-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":84},{"nctId":"NCT03332498","phase":"PHASE1, PHASE2","title":"Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-01-24","conditions":"Colon Cancer, Colorectal Cancer, Colorectal Carcinoma","enrollment":40},{"nctId":"NCT04375397","phase":"PHASE2","title":"Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-06-06","conditions":"CoronaVirus Induced Disease-2019 (COVID-19)","enrollment":46},{"nctId":"NCT02301156","phase":"PHASE3","title":"Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"TG Therapeutics, Inc.","startDate":"2015-01-27","conditions":"Chronic Lymphocytic Leukemia","enrollment":126},{"nctId":"NCT04209621","phase":"PHASE2","title":"Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-07-31","conditions":"Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL)","enrollment":3},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT03045328","phase":"PHASE2","title":"Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL","status":"COMPLETED","sponsor":"Steven E. Coutre","startDate":"2017-09-26","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":22},{"nctId":"NCT02165397","phase":"PHASE3","title":"Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-07-07","conditions":"Waldenström's Macroglobulinemia","enrollment":181},{"nctId":"NCT03755947","phase":"PHASE2","title":"Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Grupo Cooperativo de Hemopatías Malignas","startDate":"2018-12-01","conditions":"B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)","enrollment":3},{"nctId":"NCT02264574","phase":"PHASE3","title":"A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-10-06","conditions":"Chronic Lymphocytic Leukemia, Small-Cell Lymphoma","enrollment":229},{"nctId":"NCT01611090","phase":"PHASE3","title":"A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-09-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":578},{"nctId":"NCT02801578","phase":"PHASE2, PHASE3","title":"A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-07-06","conditions":"Chronic Lymphocytic Leukemia","enrollment":11},{"nctId":"NCT01752426","phase":"PHASE1, PHASE2","title":"Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-12-17","conditions":"Leukemia","enrollment":30},{"nctId":"NCT01578707","phase":"PHASE3","title":"A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2012-06","conditions":"Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":391},{"nctId":"NCT03301207","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-20","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":25},{"nctId":"NCT01980628","phase":"PHASE2","title":"Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-12","conditions":"Marginal Zone Lymphoma, B-cell Lymphoma","enrollment":63},{"nctId":"NCT01520519","phase":"PHASE2","title":"Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-27","conditions":"Leukemia","enrollment":40},{"nctId":"NCT02195869","phase":"PHASE1, PHASE2","title":"Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-07-14","conditions":"Graft Versus Host Disease","enrollment":45},{"nctId":"NCT02973399","phase":"PHASE1","title":"Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL","status":"TERMINATED","sponsor":"Esanex Inc.","startDate":"2017-02-07","conditions":"Cancer","enrollment":5},{"nctId":"NCT02914327","phase":"PHASE1","title":"Safety and Activity of SNX-5422 Plus Ibrutinib in CLL","status":"WITHDRAWN","sponsor":"Esanex Inc.","startDate":"2017-02-02","conditions":"Cancer","enrollment":""},{"nctId":"NCT01973387","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-10-28","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":160},{"nctId":"NCT01722487","phase":"PHASE3","title":"Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-03","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":269},{"nctId":"NCT01569750","phase":"PHASE1","title":"A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06-14","conditions":"CD20-positive B-cell Non-Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT01779791","phase":"PHASE2","title":"A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-04-17","conditions":"Lymphoma","enrollment":110},{"nctId":"NCT02381080","phase":"PHASE1","title":"Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05-19","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":26},{"nctId":"NCT02437019","phase":"","title":"Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","status":"APPROVED_FOR_MARKETING","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT02877225","phase":"PHASE1","title":"Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-29","conditions":"Healthy","enrollment":103},{"nctId":"NCT01744691","phase":"PHASE2","title":"A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2013-01","conditions":"Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion","enrollment":145},{"nctId":"NCT02169180","phase":"PHASE2","title":"Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2014-08","conditions":"Lymphoma, Mantle-cell","enrollment":16},{"nctId":"NCT02129062","phase":"PHASE2","title":"Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04","conditions":"Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":3},{"nctId":"NCT02780830","phase":"PHASE1","title":"AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2016-06","conditions":"Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT02271438","phase":"PHASE1","title":"A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-10","conditions":"Healthy","enrollment":28},{"nctId":"NCT01599949","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08","conditions":"Mantle Cell Lymphoma","enrollment":120},{"nctId":"NCT01820936","phase":"PHASE1","title":"A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-03","conditions":"Healthy Volunteers","enrollment":52},{"nctId":"NCT01866033","phase":"PHASE1","title":"A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-06","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT01969266","phase":"PHASE1","title":"A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-10","conditions":"Healthy Volunteer","enrollment":8},{"nctId":"NCT01626651","phase":"PHASE1","title":"A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-06","conditions":"Healthy","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Imbruvica"],"phase":"phase_3","status":"active","brandName":"Ibrutinib Oral Capsule","genericName":"Ibrutinib Oral Capsule","companyName":"Pharmacyclics LLC.","companyId":"pharmacyclics-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling in B cells and other immune cells, leading to reduced proliferation and survival of malignant B cells. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}